Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veena John

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
ACG Case Reports Journal|January 14, 2022
Olaparib-Induced Immune-Mediated Liver InjuryMohammad Alshelleh, Jennifer Park, Veena John, et al.
Journal of Pharmacy Practice|April 19, 2022
A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer PatientsChung-Shien Lee, Jennifer Hernandez, Connie Liang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 15, 2011
Percutaneous insertion of peritoneal portsCraig R Greben, Greg E Goldstein, John Lovecchio, et al.
Journal of Gastrointestinal Cancer|June 11, 2025
Hepatic Yolk Sac Tumor: A Systematic Review of Presentation, Diagnosis, and TreatmentBrittany Kwait, Awais Paracha, Umar Durrani, et al.
Gynecologic Oncology Reports|June 9, 2025
Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic reviewMahalia Huba, Fahad Hussain, Saimanoj Guntaka, et al.
JCO Precision Oncology|September 29, 2021
Clinical Implications of Genomic Loss of Heterozygosity in Endometrial CarcinomaBethany Bustamante, Risha Sinha, Briana Rice, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
BMJ Open|June 5, 2025
Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trialMarina Frimer, Arielle Katcher, Pegah Blustein, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
ACG Case Reports Journal|January 14, 2022
Olaparib-Induced Immune-Mediated Liver InjuryMohammad Alshelleh, Jennifer Park, Veena John, et al.
Journal of Pharmacy Practice|April 19, 2022
A Real World Perspective of PARP Inhibitor Use in Gynecological Cancer PatientsChung-Shien Lee, Jennifer Hernandez, Connie Liang, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 15, 2011
Percutaneous insertion of peritoneal portsCraig R Greben, Greg E Goldstein, John Lovecchio, et al.
Journal of Gastrointestinal Cancer|June 11, 2025
Hepatic Yolk Sac Tumor: A Systematic Review of Presentation, Diagnosis, and TreatmentBrittany Kwait, Awais Paracha, Umar Durrani, et al.
Gynecologic Oncology Reports|June 9, 2025
Non-bacterial thrombotic endocarditis in ovarian cancer: A systematic reviewMahalia Huba, Fahad Hussain, Saimanoj Guntaka, et al.
JCO Precision Oncology|September 29, 2021
Clinical Implications of Genomic Loss of Heterozygosity in Endometrial CarcinomaBethany Bustamante, Risha Sinha, Briana Rice, et al.
Nature Communications|March 27, 2026
Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trialRebecca L Porter, Yinglu Zhou, Nebiyat Eskndir, et al.
BMJ Open|June 5, 2025
Maintenance with niraparib in patients with stage III, stage IV, chemo-naïve recurrent or platinum-sensitive recurrent uterine serous carcinoma: study protocol for a phase II clinical trialMarina Frimer, Arielle Katcher, Pegah Blustein, et al.
Pageof 2